Elspeth McIntosh began her career in the pharmaceutical industry in 1993, initially working in clinical research, before moving into Pharmacovigilance. She has extensive experience of all aspects of pharmacovigilance and has been a small company QPPV since 1999, dealing with innovative, generic and biotech/biological products. Elspeth set up Castle Pharmacovigilance in 2009 and post Brexit she is a UK QPPV and UK National Contact Person for several small pharma companies and provides general PV support to a wide range of pharma companies.

ANNA-SHARI MELIN is a leader of the Global Life Sciences practice in Munich. She is focused on EU & German regulatory compliance, ESG, & private equity/M&A. Her clients span pharmaceuticals, biotechnology, medical devices, food, cosmetics, and consumer goods. With extensive experience in product lifecycle regulatory matters, she advises on clinical trials, GMP compliance, PV supply chain management, marketing, and compliance issues, as well as due diligence for life sciences transactions. Representing clients before EU & German authorities, she has handled notable cases, including pay-for-delay appeals. She co-leads Sidley’s PV benchmarking group & the Life Sciences ESG Roundtable, fostering discussion on evolving EU ESG regulations.

Magnus Ysander is the EU and UK QPPV for the AstraZeneca group of companies since 2015. From 2022 he also has the same role for Alexion. Based in Gothenburg, Sweden he joined the company in 2002 and have had several specialist, oversight and line managerial roles within the global AstraZeneca pharmacovigilance organisation. Magnus is a MD and has previously worked as a certified Orthopedic Surgeon. He is a member of EFPIA Pharmacovigilance Expert Group and the Program Committee for the DIA QPPV Forum.